In this new Trade To Black podcast, TDR Founder Shadd Dales and contributor Anthony Varrell interview the founder of Apeiron Investment Group, Christian Angermayer. Aperion is best known for deep ...

Wood said the transaction validates Christian Angermayer’s long-term psychedelic medicine vision. Lilly will pay $6.75 per share, including $2.8 billion upfront and up to $1 billion in milestones. The ...

Turn on, tune in, drop out: Christian Angermayer has cemented his place in psychedelics by selling biotech AtaiBeckley to Eli Lilly in the biggest acquisition in the industry. "The future is ...

• Apeiron and other key shareholders enter into voluntary lock-up agreements• This voluntary lock-up extends trading restrictions by 24 months for Apeiron and 12 months for other investors• ...

Christian Angermayer is a big fan of magic mushrooms. So much so he has invested millions into them. That is because the German-born, London-based entrepreneur is betting on the power of pyschedelics ...

n a suite on the fourth floor of the Four Seasons in Austin, Texas, the German billionaire Christian Angermayer is talking about his newest investment: the Enhanced Games, a 21st-century Olympics on ...

Christian Angermayer, the founder and Chairman of the Board of Apeiron Investment Group, is adding more than $1,000,000 in shares of ATAI Life Sciences NV (NASDAQ:ATAI). Angermayer laid out the ...

Atai Life Sciences founder Christian Angermayer says holding Bitcoin could be a way for biotech firms to survive the blisteringly long approval process required to bring their drugs to market.

Investors are increasingly drawn to Europe amid tariff uncertainty, but startups face still obstacles going public on European exchanges. Swiss real estate heir Robin Lauber and German billionaire ...